A new class of myeloma drug was approved on a more sensitive test of remission
Zenbexus didn't have to outlive patients in a control arm to win approval — it had to clear their bone marrow of detectable disease faster. That shortcut is becoming the norm, not the exception.
The FDA granted accelerated approval on 13 August to Zenbexus (iberdomide), Bristol Myers Squibb's first drug in a new class called CELMoDs, for adults with multiple myeloma who have relapsed after at least one prior treatment line that included a proteasome inhibitor and an immunomodulatory drug [s1]. It's approved in combination with daratumumab, hyaluronidase-fihj, and dexamethasone — a regimen BMS calls ZDd [s1].
What makes it a new drug class, not just a new drug
CELMoD stands for cereblon E3 ligase modulator. In practical terms, these are oral drugs that redirect a cell's own protein-disposal machinery — the cereblon E3 ligase complex — to tag and destroy specific proteins the cancer depends on, proteins that were previously considered undruggable by conventional small molecules [s1]. BMS describes iberdomide as a more potent successor to its older IMiD (immunomodulatory drug) class, which includes older myeloma standbys, engineered to degrade its targets more efficiently [s1]. Chief Medical Officer Cristian Massacesi called it the arrival of "a new treatment class" for myeloma, and BMS's framing is that this mechanism opens the door to combination regimens that weren't possible with the older drug family [s1].
The approval didn't wait for survival data — it waited for something else
Zenbexus was evaluated in EXCALIBER-RRMM, a two-stage, randomized, open-label Phase 3 trial that enrolled 939 patients, comparing ZDd against daratumumab-bortezomib-dexamethasone (DVd) [s1]. But the number that earned accelerated approval isn't a survival or progression-free-survival figure — it's minimal residual disease (MRD)-negative complete response, measured in a 420-patient subset (207 on ZDd, 213 on DVd) after a median follow-up of 16 months [s1]. MRD-negative means a highly sensitive test found no detectable cancer cells left in the bone marrow, a proxy that shows up faster than "did the patient's disease progress" or "is the patient still alive."
ZDd hit that endpoint in 41% of patients (95% CI: 34–48%) versus 21% on DVd (95% CI: 15–27%), a difference BMS reports as statistically significant (p<0.0001) [s1]. That's real and its confidence intervals don't overlap, which matters. But an MRD-negative result is not the same claim as "patients on Zenbexus lived longer" — it's a biomarker regulators accepted as reasonably likely to predict that outcome, which is exactly what "accelerated approval" means and why it comes with a post-approval obligation to confirm the benefit with longer follow-up. BMS's own release does not report an overall response rate or survival comparison alongside the MRD figures, so readers should treat the clinical benefit as probable, not yet proven in the strongest sense.
The risks are serious enough to require a restricted program
Zenbexus carries a boxed warning — the FDA's strongest — for two separate risks. It is contraindicated in pregnancy: BMS's prescribing information states it "can cause birth defects or embryo-fetal death in humans," and patients who can become pregnant must have two negative pregnancy tests before starting [s1]. Separately, the drug carries an increased risk of venous and arterial blood clots — deep vein thrombosis, pulmonary embolism, heart attack, and stroke — serious enough that anti-clotting medication is recommended alongside treatment [s1]. Because of the pregnancy risk specifically, Zenbexus is only available through a restricted distribution program (a REMS) that requires prescriber certification and patient enrollment with contraception and monitoring compliance [s1]. Standard dosing is 1 mg daily for the first 21 days of each 28-day cycle, with a lower every-other-day dose for patients with significant kidney impairment [s1].
What to watch next
The confirmatory trial data BMS owes the FDA — actual progression-free survival or overall survival results, not just the MRD proxy — will determine whether this accelerated approval converts to full approval or gets walked back, as has happened to other accelerated-approval oncology drugs when confirmatory data disappointed. Also worth tracking: how oncologists sequence ZDd against existing regimens now that a first-relapse-eligible CELMoD option exists, and whether BMS's other CELMoD candidates in development follow the same MRD-based accelerated pathway rather than waiting for survival data.
Sources
Brazil's regulator approved 18 new cancer drugs in five years. The FDA approved 73.
A comparison of FDA, EMA and ANVISA decisions from 2020 to 2024 finds Brazilian approvals arriving about a year later. A second study clocks the wait for public-system financing in years, not months.
A second oral HER2 lung-cancer drug clears FDA on tumour response, not survival
Hyrnuo (sevabertinib) is cleared for previously treated HER2-mutant NSCLC on response rate alone. The confirmatory trial that must justify it does not report until 2029.
FDA clears first gene therapy for a rare disorder managed with round-the-clock cornstarch
GENGLYCOS treats the cause of glycogen storage disease type Ia, not just the symptoms cornstarch regimens manage — but it carries a long list of serious risks and an accelerated-approval asterisk.
China approved more cancer drugs than the FDA over six years, and reviewed them slower
A comparison of 2020–2025 approvals finds 94 novel oncology drugs from the NMPA against 87 from the FDA, with China's volume overtaking from 2023. The speed and first-in-class figures run the other way.